Melbourne, Australia, 1 September 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, today announces it has been awarded AUD $2,980,000 in funding from Australia’s Biointelect Venturer as part of its inaugural funding round. The funding will support a […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2026-09-01 07:30:352026-09-01 07:30:35ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent […]
Melbourne, Australia, 11 May 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the successful completion of Part A of its Phase IIa community study of INNA-051, and progression to Part B. INNA-051 is a virus-agnostic, once-weekly, dry powder nasal […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2026-05-11 07:29:362026-05-11 07:31:37ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 23 April 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment of Melissa Faris as an independent Non-Executive Director. Melissa is Chief Business Officer of OMass Therapeutics, a leading UK-based private biotechnology company, and was previously […]
Melbourne, Australia, 29 January 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, today announces it has dosed the first participants in its Phase II community study of INNA-051, with the first participant dosing now completed. INNA-051 is a virus-agnostic, once-weekly, dry […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2026-01-29 00:01:542026-03-09 13:46:00ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]
http://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svg00Chris Kellyhttp://enarespiratory.com/wp-content/uploads/2024/10/Ena_Respiratory_RGB_Color_REV.svgChris Kelly2025-10-22 04:57:592025-10-24 23:00:54ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 1 September 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, today announces it has been awarded AUD $2,980,000 in funding from Australia’s Biointelect Venturer as part of its inaugural funding round. The funding will support a […]
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent […]
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 11 May 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the successful completion of Part A of its Phase IIa community study of INNA-051, and progression to Part B. INNA-051 is a virus-agnostic, once-weekly, dry powder nasal […]
ENA Respiratory Appoints Melissa Faris to Board
Melbourne, Australia, 23 April 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment of Melissa Faris as an independent Non-Executive Director. Melissa is Chief Business Officer of OMass Therapeutics, a leading UK-based private biotechnology company, and was previously […]
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 29 January 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, today announces it has dosed the first participants in its Phase II community study of INNA-051, with the first participant dosing now completed. INNA-051 is a virus-agnostic, once-weekly, dry […]
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]